Some cancer cells just won’t commit: Why that might be good news for neuroblastoma cancer patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Jun-2025 15:10 ET (28-Jun-2025 19:10 GMT/UTC)
City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research
Tony Hunter, Ph.D., to be honored at the 2025 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship in Washington, D.C., for his landmark discovery that opened the field of tyrosine kinase signaling and revolutionized cancer treatment.
A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within tumours, opening doors for more targeted therapies for patients.
Cells depend on the precise reading of DNA sequences to function correctly. This process, known as gene expression, determines which genetic instructions are activated. When this fails, the wrong parts of the genome can be activated, leading to cancers and neurodevelopmental disorders. Scientists at the University of Geneva (UNIGE) have identified two proteins that play a key role in regulating this essential mechanism, paving the way for promising new treatments that could be more effective and less toxic than those currently available. Their findings are published in Nature Communications.